Janet Wale

TL;DR: The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines, as well as develop exemplar models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure.

TL;DR: A review of authority activities in over 30 countries and regions to develop new models to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities and the implications for all major stakeholder groups.

TL;DR: Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities.

TL;DR: In this paper, a number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models.

TL;DR: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines.